Topics

Post-Hoc Analyses of Radicava Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency

15:24 EDT 2 May 2019 | Speciality Pharma Journal

JERSEY CITY, N.J., May 2, 2019 /PRNewswire/ — Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced results from a post-hoc analysis that showed how the RADICAVA® (edaravone) Phase 3 study design minimized heterogeneity of the study population to successfully demonstrate a treatment effect in amyotrophic lateral sclerosis (ALS) in 24 weeks.1 Because ALS is a …

Original Article: Post-Hoc Analyses of Radicava Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency

NEXT ARTICLE

More From BioPortfolio on "Post-Hoc Analyses of Radicava Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency"

Quick Search